At Bristol Gregg had realized that a protein called the microsomal triglyceride transfer protein (MTP) had gone defective in his old patients, and he set out to come up with a drug that blocked it in heart disease patients.

FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug

Torcetrapib aims to raise good cholesterol, or high-density lipoprotein, by blocking the cholesterol ester transfer protein.

FORBES: Magazine Article

Merck unveiled another kind of HDL-raiser, a drug to inhibit the cholesterol ester transfer protein (CETP).

FORBES: Magazine Article

All the drugs work by blocking the cholesterol ester transfer protein.

FORBES

Researchers got excited about HDL in the late 1990s because they found a way to raise it by blocking a molecule called cholesterol ester transfer protein (CETP).

FORBES: Good Cholesterol Goes Bad

Merck and Roche are also developing other HDL-raising drugs that work by inhibiting the cholesterol-ester transfer protein, similar to a Pfizer drug that failed several years ago.

FORBES: HDL-Raising Drug Fails To Show Benefit In Government Study

Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.

FORBES: Magazine Article

My experiments make use of sophisticated spectroscopy measurements of resonance energy transfer, to help gauge the accuracy of computational simulations of protein dynamics.

WHITEHOUSE: Engage and Connect

They do this by interfering with the activity of the messenger RNA strands that transfer genetic information from the cell's nucleus to its protein-making machinery.

ECONOMIST: DNA computing